Immunotec Inc.
TSX CROISSANCE : IMM
TSX VENTURE : IMM

Immunotec Inc.

July 07, 2009 23:59 ET

2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process

MONTREAL, July 7 - Immunotec Inc. (TSX-V: IMM) announced
today that the Natural Health Products Directorate (NHPD) - a division of
Health Canada responsible for evaluating the safety, efficacy and quality of
natural health products (NHPs) - granted authorization for Immunotec to
conduct a clinical trial of IMMUNOCAL® in elderly persons.

Aging is typically associated with a decrease in skeletal muscle mass and
muscle function, which contributes decisively to disability in old age and to
a loss of quality of life. Resistance training exercise can increase muscle
strength, function and mass in older adults.

The primary aim of this study is to determine whether taking a
cysteine-rich whey protein isolate (IMMUNOCAL®) compared to casein (a milk
protein used as control, which contains little cysteine) may optimize the
quality of life in the elderly. The consumption of these proteins will be
evaluated in association with resistance training to determine if the
combination of Immunocal® with exercise will provide significant gains in
muscle strength, muscle mass and cognitive functions, compared to the same
training program combined with taking casein, the control protein. Benefits in
these fields can be translated to improved quality of life for elderly
persons.

The Principal Investigator, Dr. Rémi Rabasa-Lhoret, MD, PhD, Associate
Research Professor and Metabolic Unit Laboratory Director, Institut de
recherches cliniques de Montréal (IRCM) and his research team are very
enthusiastic about the prospects of the trial. "Immunotec should be commended
for initiating and supporting this very important research study of its lead
product "Immunocal" in aging. It is rare to see companies in this field
conducting double blind randomized studies with a control group. The focus of
the study is highly relevant for people over the age of 65. Assessing the
combined effects of exercise and supplementation with cysteine-rich whey
protein isolate (IMMUNOCAL®) as well as the potential impact on important
functions, such as muscle strength and cognition may provide significant
benefits," said Dr. Rabasa-Lhoret.

"NHPD, Health Canada's clearance of the clinical application for our
Immunocal® trial adds to our significant accomplishments and continued
commitment in research," said Mr. James Northrop, President and CEO of
Immunotec Inc. "This marks the first, controlled clinical study of
Immunocal® in an elderly population. Furthermore, we are delighted with the
fact that this study will be run at IRCM - a research center in the province
of Quebec with an excellent reputation in Canada and internationally."

About Immunocal®

Immunocal®, Immunotec's cornerstone product, is a cysteine- rich whey
protein isolate- a dietary natural health supplement, developed and marketed
by Immunotec over the past 10 years. It secured Health Canada regulatory
approval to market the product in Canada and an NPN (Natural Product Number)
on October 31, 2007 for the health claim "Immunocal is a natural source of the
glutathione precursor cysteine for the maintenance of a strong immune system".

About Immunotec Inc.

Immunotec is engaged primarily in the development and marketing of
natural health products, dietary supplements, vitamins and personal care
products, many of which are manufactured on its behalf by third parties.
Immunotec's products are distributed and sold in Canada, the United States,
Korea, Ireland and the United Kingdom through a network marketing system and
in other countries through exclusive distributorship agreements. Immunotec's
investment in this study is another reflection of its ongoing commitment to
research and development.

About IRCM Inc.

Established in 1967, the IRCM (http://www.ircm.qc.ca/en/) now has 35
research units specialized in areas as diverse as immunity and viral
infections, cardiovascular and metabolic diseases, cancer, neurobiology and
development, systems biology and medicinal chemistry, clinical research and
bioethics. It has a staff of more than 450 people. The IRCM is an independent
institution, affiliated with the Université de Montréal and has built, over
the years, a close collaboration with McGill University. The IRCM Outpatient
Clinic is now associated with the CHUM (Centre hospitalier de l'Université de
Montréal).

Contact Information

  • John H. Molson, Vice-President, Research & Development, Immunotec Inc., (450) 510-4450, Fax: (450) 424-9993, jmolson@immunotec.com;
    Clare Malbon, R&D Dept., (450) 424-9992 ext 2377